Development and Verification of an Immune-Based Gene Signature for Risk Stratification and Immunotherapeutic Efficacy Assessment in Gastric Cancer

<div>Assessment of sensitivity of chemotherapy drugs and prediction of small molecular compounds based on the risk score. (a) Box plots for estimated IC50 values of A.770041, ABT.263, AMG.706, AP.24534, AS601245, Bicalutamide, BMS.536924, and AZD6482 in high- and low-risk gastric cancer samples. (b) Mechanisms of action shared by small molecular inhibitors.</div>

Disease Markers

fig7

Figure 7

Figure 7: Development and Verification of an Immune-Based Gene Signature for Risk Stratification and Immunotherapeutic Efficacy Assessment in Gastric Cancer 

Figure 7 | Development and Verification of an Immune-Based Gene Signature for Risk Stratification and Immunotherapeutic Efficacy Assessment in Gastric Cancer 